New Ocriplasmin Clinical and Health Economic Data Presented at ASRS 2017 in Boston
(WorldNews Belgium)

Leuven, Belgium, 16 August 2017 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, announced today that further ocriplasmin clinical and health economic data was presented at the 35th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS). The meeting was held from August 11th through August 15th, 2017 in Boston, MA. The first poster presentation was`Comparison of Visual...